HK1083452A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
HK1083452A1
HK1083452A1 HK06103477.0A HK06103477A HK1083452A1 HK 1083452 A1 HK1083452 A1 HK 1083452A1 HK 06103477 A HK06103477 A HK 06103477A HK 1083452 A1 HK1083452 A1 HK 1083452A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
valsartan
compositions
bioavailable
hydrate
Prior art date
Application number
HK06103477.0A
Other languages
English (en)
Inventor
Sabina Maria Ganter
Robert Frank Wagner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1083452A1 publication Critical patent/HK1083452A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06103477.0A 2000-06-22 2006-03-20 Pharmaceutical compositions HK1083452A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
HK1083452A1 true HK1083452A1 (en) 2006-07-07

Family

ID=24400655

Family Applications (2)

Application Number Title Priority Date Filing Date
HK03104842.9A HK1052868A1 (zh) 2000-06-22 2003-07-08 藥物組合物
HK06103477.0A HK1083452A1 (en) 2000-06-22 2006-03-20 Pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK03104842.9A HK1052868A1 (zh) 2000-06-22 2003-07-08 藥物組合物

Country Status (21)

Country Link
EP (2) EP2072049A3 (xx)
JP (3) JP2003535895A (xx)
KR (2) KR100525341B1 (xx)
CN (2) CN100450478C (xx)
AU (2) AU2001285768B2 (xx)
BR (1) BR0111868A (xx)
CA (1) CA2411882C (xx)
CZ (1) CZ20024180A3 (xx)
EC (1) ECSP024389A (xx)
HK (2) HK1052868A1 (xx)
HU (1) HUP0301390A3 (xx)
IL (2) IL153428A0 (xx)
MX (1) MXPA02012683A (xx)
NO (1) NO20026123L (xx)
NZ (2) NZ540748A (xx)
PL (1) PL358290A1 (xx)
RU (1) RU2333757C2 (xx)
SG (1) SG162605A1 (xx)
SK (1) SK18062002A3 (xx)
WO (1) WO2001097805A2 (xx)
ZA (1) ZA200210359B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298298A3 (en) * 1998-12-23 2011-05-11 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
CA2472399C (en) * 2002-01-17 2012-02-21 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
DK2033629T3 (da) 2004-12-24 2013-02-04 Krka Fast farmaceutisk sammensætning omfattende valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
CN101888829A (zh) 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
WO1995024901A1 (en) 1994-03-17 1995-09-21 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
DE69624253T2 (de) * 1995-10-06 2003-08-07 Novartis Ag Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
ES2189940T3 (es) * 1996-02-29 2003-07-16 Novartis Ag Antagonista de receptor at1 para la estimulacion de la apoptosis.
IL124935A (en) * 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dissolvable fungicidal preparations contain itraconazole with improved bioavailability
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
EP2298298A3 (en) * 1998-12-23 2011-05-11 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SK14642002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor

Also Published As

Publication number Publication date
CA2411882C (en) 2011-09-06
RU2333757C2 (ru) 2008-09-20
CZ20024180A3 (cs) 2003-04-16
BR0111868A (pt) 2003-07-01
ZA200210359B (en) 2003-11-13
EP1296677A2 (en) 2003-04-02
HK1052868A1 (zh) 2003-10-03
NO20026123D0 (no) 2002-12-19
CN100450478C (zh) 2009-01-14
MXPA02012683A (es) 2003-04-25
CN1437469A (zh) 2003-08-20
NZ522953A (en) 2005-10-28
HUP0301390A3 (en) 2005-04-28
AU2001285768B2 (en) 2005-03-10
SG162605A1 (en) 2010-07-29
CA2411882A1 (en) 2001-12-27
KR100659644B1 (ko) 2006-12-21
KR100525341B1 (ko) 2005-11-02
JP2003535895A (ja) 2003-12-02
CN1679551A (zh) 2005-10-12
IL153428A (en) 2013-12-31
EP2072049A2 (en) 2009-06-24
CN1221256C (zh) 2005-10-05
HUP0301390A2 (hu) 2003-11-28
PL358290A1 (en) 2004-08-09
JP2007091758A (ja) 2007-04-12
IL153428A0 (en) 2003-07-06
ECSP024389A (es) 2003-02-06
AU8576801A (en) 2002-01-02
NO20026123L (no) 2003-02-18
KR20050085978A (ko) 2005-08-29
NZ540748A (en) 2007-04-27
WO2001097805A3 (en) 2002-08-29
EP2072049A3 (en) 2009-12-30
SK18062002A3 (sk) 2003-07-01
WO2001097805A2 (en) 2001-12-27
KR20030019450A (ko) 2003-03-06
JP2012211200A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
HK1083452A1 (en) Pharmaceutical compositions
CA2427815A1 (en) Controlled release hydrocodone formulations
IL150696A0 (en) Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof
MXPA03006476A (es) Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas.
TWI315204B (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
IL212075A0 (en) Pharmaceutical compositions comprising a combination of a renin inhibitor and at least one therapeutic agent and uses thereof for the manufacture of medicaments for the prevention of, delay of progression of, or treatment of a disease
BG103882A (en) Voriconazol-containing pharmaceutical compositions
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
PL342988A1 (en) Novel galenic formulations of meloxicam for oral administration
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
IL179017A0 (en) Solid oral dosage form comprising valsartan
DE69413237D1 (en) Plättchenaggregationsinhibitoren
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
HK1039273A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
AU1549500A (en) Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
DE69530123D1 (en) Plättchenaggregationsinhibitoren
IL161991A0 (en) Oral dosage form of a sulfonamide prodrug such as parecoxib
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HUP0201667A3 (en) Oral form of administration
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény